Value Investor
Start free

Contineum Therapeutics

CTNM on Nasdaq. Market value $102m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

We have not checked this company yet

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 102 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

8 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 3 sold $2m, $2m of it under preset trading plans.

  • Stengone Carmine N.
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    8 September 2026
    Shares
    2,500
    Price
    $16.46
    Value
    $41,142
  • Stengone Carmine N.
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    3 August 2026
    Shares
    2,500
    Price
    $16.01
    Value
    $40,029
  • Lorrain Daniel S.
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    9 July 2026
    Shares
    25
    Price
    $16.00
    Value
    $400
  • Lorrain Daniel S.
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    8 July 2026
    Shares
    1,015
    Price
    $16.00
    Value
    $16,240
  • Stengone Carmine N.
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    8 July 2026
    Shares
    2,500
    Price
    $16.00
    Value
    $40,000
  • Lorrain Daniel S.
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    8,353
    Price
    $15.84
    Value
    $132,290
  • Lorrain Daniel S.
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    30 June 2026
    Shares
    28,826
    Price
    $16.04
    Value
    $462,288
  • Watkins Tim
    CMO & Head of Development
    Sold
    under a preset trading plan
    Date
    30 June 2026
    Shares
    10,833
    Price
    $16.02
    Value
    $173,590
  • Stengone Carmine N.
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    30 June 2026
    Shares
    10,000
    Price
    $16.01
    Value
    $160,080
  • Lorrain Daniel S.
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    1 June 2026
    Shares
    4,170
    Price
    $13.16
    Value
    $54,877

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 30 Jul 2026 and 6 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.